Biocon Biologics' Yesintek, a biosimilar to Stelara, has secured significant market access in the US, covering over 100 ...

The drug has been chosen as the sole ustekinumab by BCBSM, Florida Healthcare Plan, and other closed-door health systems.

Biocon Biologics has secured multiple market access agreements for Yesintek (ustekinumab-kfce), its biosimilar to Stelara ...

Artificial intelligence can improve care for patients with primary immunodeficiencies, but human input is still necessary, ...

The entire contents of the call, including the presentation and question-and-answer ... independent national lab to be selected to the Optum Health Preferred Lab Network. The Optum Health PLN ...

Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced the Company has secured multiple market access ...

Biocon Biologics secures multiple market access agreements in the US for its biosimilar, Yesintek, for treating Crohn's ...

Biocon Biologics (BBL), subsidiary of Biocon, today announced the Company has secured multiple market access agreements for Yesintek (ustekinumab-kfce), its biosimilar to Stelara (ustekinumab). The ...

The entire contents of the call, including the presentation and question-and-answer ... to be selected to the Optum Health preferred lab network. The Optum Health PLN requires labs to meet ...

Herbert Simon, one of the early theorists of artificial intelligence, delivered a presentation on AI in Holmes Theater ... director of Artificial Intelligence & Cognitive Technology at Optum ...